HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearchCompany Lookup

ACP Names Semaglutide, Tirzepatide as First-Line Pharmacotherapy for Obesity

ACP Names Semaglutide, Tirzepatide as First-Line Pharmacotherapy for Obesity

By AJMC · Jun 15, 2026 · via AJMC

This is an aggregated industry headline. Read the full story at AJMC

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineAJMC
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Shionogi's "Got the Call, Make the Call" campaign for COVID antiviral Xocova kicks off with a TV ad depicting …
Jul 31, 2026
The WeekFierceBiotech ↗
Apnimed has raised $192 million for its upsized IPO, with the proceeds earmarked to fund the launch of its sle…
Jul 31, 2026
FDA Sets FY 2027 PDUFA Fees, With Slightly Lower Application and Program Charges
The WeekBriefing
FDA’s July 30 notice sets FY 2027 PDUFA fees below FY 2026 levels for clinical-data applications, non-clinical…
Jul 31, 2026